Chromocell Therapeutics Corporation (CHRO)
USD 0.59
(-4.76%)
USD 0.59
(-4.76%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | 199.93 Thousand |
| Cost of Revenue | 2.57 Million | 391.73 Thousand | 209.04 Thousand | 138.58 Thousand |
| Gross Profit | -2.57 Million | -391.73 Thousand | -209.04 Thousand | 61.34 Thousand |
| Operating Expenses | 6.86 Million | 2.31 Million | 838.99 Thousand | 1.55 Million |
| Selling, General and Administrative Expenses | 4.28 Million | 1.92 Million | 629.94 Thousand | 1.41 Million |
| Research and Development Expenses | 2.57 Million | 391.73 Thousand | 209.04 Thousand | 138.58 Thousand |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 6.86 Million | 2.31 Million | 838.99 Thousand | 1.55 Million |
| Operating Income | -6.86 Million | -2.31 Million | -839 Thousand | -1.35 Million |
| Interest Expense | 518.5 Thousand | 140.43 Thousand | 253.00 | 1676.00 |
| Income Tax Expense | - | -690.45 Thousand | -838.99 Thousand | -1.35 Million |
| Earnings before Tax | -7.38 Million | -2.45 Million | -595.38 Thousand | -660.58 Thousand |
| Net Income | -7.38 Million | -2.45 Million | -595.38 Thousand | -660.58 Thousand |
| Earnings Per Share Basic | -1.28 | -0.43 | -0.10 | -0.11 |
| Earnings Per Share Diluted | -1.28 | -0.43 | -0.10 | -0.11 |
| Weighted Average Shares Outstanding | 5.76 Million | 5.76 Million | 5.76 Million | 5.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 5.76 Million | 5.76 Million | 5.76 Million | 5.76 Million |
| Gross Margin | - | - | - | 0.31 |
| EBIT Margin | - | - | - | -6.77 |
| Profit Margin | - | - | - | -3.30 |
| EBITDA | -6.86 Million | -1.62 Million | - | - |
| Earnings Before Tax Margin | - | - | - | -6.77 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 12.96 | 466.6 Thousand | 2.57 Million | 2.57 Million | - | 49.95 Thousand |
| Gross Profit | -12.96 | -466.6 Thousand | -2.57 Million | -2.57 Million | - | -49.95 Thousand |
| Operating Expenses | 1.76 Million | 1.93 Million | 3.87 Million | 6.86 Million | 1.29 Million | 777.16 Thousand |
| Selling, General and Administrative Expenses | 1.75 Million | 1.46 Million | 1.58 Million | - | 1.24 Million | 727.2 Thousand |
| Research and Development Expenses | 12.95 Thousand | 466.6 Thousand | 2.29 Million | - | 49.13 Thousand | 49.95 Thousand |
| Other Expenses | 3527.00 | - | - | - | - | - |
| Cost and Expenses | 1.76 Million | 1.93 Million | 3.87 Million | 6.86 Million | 1.29 Million | 777.16 Thousand |
| Operating Income | -1.76 Million | -1.93 Million | -3.87 Million | -6.86 Million | -1.29 Million | -777.16 Thousand |
| Interest Expense | 11.06 Thousand | 628.34 Thousand | 160.33 Thousand | 518.5 Thousand | 130 Thousand | 176.18 Thousand |
| Income Tax Expense | -1764.09 | -1.93 Million | -3.87 Million | -6.86 Million | -1.29 Million | -777.16 Thousand |
| Earnings before Tax | -1.77 Million | -2.56 Million | -4.03 Million | -7.38 Million | -1.42 Million | -953.34 Thousand |
| Net Income | -1.77 Million | -2.56 Million | -4.03 Million | -7.38 Million | -1.42 Million | -953.34 Thousand |
| Earnings Per Share Basic | -0.31 | -0.44 | -0.69 | - | -0.25 | -0.17 |
| Earnings Per Share Diluted | -0.31 | -0.44 | -0.69 | - | -0.25 | -0.17 |
| Weighted Average Shares Outstanding | 5.77 Million | 5.76 Million | 5.87 Million | 5.87 Million | 5.76 Million | 5.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 5.77 Million | 5.76 Million | 5.87 Million | 5.87 Million | 5.76 Million | 5.76 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1.76 Million | -1.93 Million | -3.87 Million | - | -1.29 Million | -777.16 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
4AB
BAJAJHLDNG
HENG
SAAM
PRM
CIM-PA